Engitix Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Engitix Therapeutics's estimated annual revenue is currently $5.2M per year.
- Engitix Therapeutics's estimated revenue per employee is $77,500
- Engitix Therapeutics's total funding is $60.4M.
Employee Data
- Engitix Therapeutics has 67 Employees.
- Engitix Therapeutics grew their employee count by -19% last year.
Engitix Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | VP Oncology and Immuno-Oncology | Reveal Email/Phone |
4 | Director Medicinal Chemistry | Reveal Email/Phone |
5 | Director, Computational Biology | Reveal Email/Phone |
6 | Director Biology | Reveal Email/Phone |
7 | Senior Director, Drug Development & Operations | Reveal Email/Phone |
8 | Senior Director, Intellectual Property | Reveal Email/Phone |
9 | Director, Fibrosis | Reveal Email/Phone |
10 | Liver fibrosis progamme leader and Director Translational Biology | Reveal Email/Phone |
Engitix Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Engitix Therapeutics?
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
keywords:N/A$60.4M
Total Funding
67
Number of Employees
$5.2M
Revenue (est)
-19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Engitix Therapeutics News
Engitix, whose backers include billionaire hedge fund manager Michael Platt, will work with Takeda to jointly develop novel therapeutics for...
The company focuses on neuroscience and immuno-oncology medicines, and its current pipeline includes therapeutics for patients with...
... Agreement with Takeda for the discovery and development of novel therapeutics for inflammatory bowel disease (IBD) builds on existing...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.2M | 67 | -67% | N/A |
#2 | $8.7M | 67 | -41% | N/A |
#3 | $8.4M | 67 | 31% | N/A |
#4 | $13.7M | 67 | 16% | N/A |
#5 | $13.3M | 67 | -14% | N/A |